Krsnaa Diagnostics (KRSNAA) Q4 24/25 earnings summary

Executive summary

• Achieved 16% year-on-year revenue growth in FY 2025, reaching INR 7,172 million, driven by increased patient volumes, pricing efficiency, and operational maturity.

• Served over 19 million patients and conducted more than 61 million tests, with a strong presence across 18 states/UTs.

• Retail diagnostic business expanded rapidly, with touchpoints growing 4X across four states and a target of 700 centers by FY27E.

• Recognized with multiple industry awards, including Best Diagnostic Lab Chain of the Year (West) and National Diagnostic Chain of the Year.

• Strategic focus on PPP leadership, integrated diagnostics, retail expansion, and quality accreditations.

Financial highlights

• FY 2025 consolidated revenue was INR 7,171.60 million (+16% YoY); EBITDA at INR 1,958 million (+34% YoY, 27% margin); net profit at INR 776.08 million (+37% YoY, 11% margin).

• Q4 FY 2025 revenue was INR 1,861 million, up 12% year-on-year; EBITDA at INR 542 million, up 23% with 29% margin.

• Board recommended a final dividend of INR 2.75 per share (55% of face value), pending AGM approval.

• Total assets as of March 31, 2025, stood at INR 12,816 million; equity at INR 8,828 million; gross debt at INR 1,655 million; cash and equivalents at INR 1,760 million.

• Basic EPS (consolidated) for FY 2025 was INR 24.04, up from INR 17.90 in FY 2023-24.

Outlook and guidance

• Expecting continued revenue and margin growth in FY 2026, with aspirations to surpass FY 2025 performance.

• Retail revenue contribution projected to rise from 3.5% in Q4 FY25 to 5-8% in FY 2026.

• Receivable days targeted to reduce to 90-100 by end of FY 2026, aided by digitized payment systems.

• CapEx for FY 2026 expected at INR 100-150 crore, with practical cash outflow significantly lower due to asset-light models.

• Plans to expand retail network to 700 centers and B2B collaborations to ~3,500 by FY27E.